Humacyte, Inc. (HUMA)
0.465
-0.01
(-2.72%)
USD |
NASDAQ |
Oct 07, 12:34
Humacyte EPS Diluted (Quarterly) : -0.1572 for June 30, 2026
EPS Diluted (Quarterly) Chart
Historical EPS Diluted (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -0.1572 |
| March 31, 2026 | -0.089 |
| December 31, 2025 | -0.1328 |
| September 30, 2025 | -0.1106 |
| June 30, 2025 | -0.2423 |
| March 31, 2025 | 0.279 |
| December 31, 2024 | -0.1649 |
| September 30, 2024 | -0.3283 |
| June 30, 2024 | -0.4755 |
| March 31, 2024 | -0.2947 |
| December 31, 2023 | -0.2423 |
| September 30, 2023 | -0.2513 |
| Date | Value |
|---|---|
| June 30, 2023 | -0.2197 |
| March 31, 2023 | -0.358 |
| December 31, 2022 | -0.0361 |
| September 30, 2022 | -0.2454 |
| June 30, 2022 | 0.3548 |
| March 31, 2022 | -0.1925 |
| December 31, 2021 | 0.4066 |
| September 30, 2021 | -0.7181 |
| June 30, 2021 | -2.894 |
| March 31, 2021 | -3.456 |
| December 31, 2020 | -2.784 |
| September 30, 2020 | -0.0017 |
EPS Diluted (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
EPS Diluted (Quarterly) Benchmarks
| Amgen, Inc. | 4.366 |
| Altimmune, Inc. | -0.1231 |
| Protalix Biotherapeutics, Inc. | 0.0458 |
| Taysha Gene Therapies, Inc. | -0.1264 |
| Agenus, Inc. | -0.0146 |
EPS Diluted (Quarterly) Related Metrics
| Net Income (Quarterly) | -36.80M |
| Revenue (Quarterly) | 0.406M |
| Total Expenses (Quarterly) | 37.21M |
| Enterprise Value | 118.92M |
| Gross Profit Margin (Quarterly) | -423.2% |
| Profit Margin (Quarterly) | -9.06K% |
| Earnings Yield | -105.3% |
| Normalized Earnings Yield | -125.72 |